Second Quarter Fy12

Managing director of Dishman Pharmaceuticals, JR Vyas expects the topline growth to be 15% or even more going forward. He also added that the bottomline will grow in the second half too.

Max India expects Rs 516cr from Max Healthcare stake sale

Deputy managing director Mohit Talwar of Max India said that profits for the life insurance business have increased 8 times and AUMs has increased 20% for the same business. Talwar expects Rs 516 crore from the Max Healthcare stake sale. He also stated that the liquidity position of Max group is very healthy.

Eros Int'l Media hopes to achieve analyst FY12 consensus

Kamal Jain, group chief financial officer (India) of the company indicated that it would continue to maintain a good cash positions going forward. He also mentioned that some big films will be released in the third quarter. He further stated that the company is inline with analyst consensus for FY12 and hopes to achieve that going forward

Nalco aims 30000-60000 tonne additional alumina sale in Q3

Nalco's second quarter results were well below the street’s estimates in terms of earnings. Chairman and director of finance BL Bagra indicated that the margins were hit because the supply from Mahanadi coal was disrupted. Nalco has been targeting 30,000-60,000 tonne of additional alumina sale in Q3.

Pipavav Defence sees order book improvement in two quarters

Pipavav Defence and Offshore Engineering expects significant improvement in the order book in two quarters, Chairman Nikhil Gandhi pointed out. Defence orders to drive order inflow in coming quarters, he added.

To book larger rev in coming quarters: Parsvnath Developers

Chairman Pradeep Jain of Parsvnath Developers clarified that the EBITDA margins eroded by rising input costs. He further elucidated that the prices were up by 20% in past six months in Delhi. Jain expects the company to book larger revenue in coming quarters. "We are in tie-up with Choice Hotels International for the hotels business," he added.

Apollo Hospital eyes to create momentum, facilities by 2013

Apollo's standalone pharmacy contributes to almost 30% of total revenues and the balance is healthcare services. Joint managing director Sunita Reddy indicated that the central, southern and eastern regions have been growing very fast. However, Apollo expects to create enough momentum and facilities by 2013 that will help the North to grow faster.

L&T's revision in inflow guidance no shocker, say experts

L&T revised its FY12 order inflow guidance to 5% from 15% earlier. While Shailesh Kanani, senior research analyst of Angel Broking feels the company has had decent order inflow, Lokesh Garg of Kotak Institutional Equities elucidates L&T’s order inflow guidance revision was expected.